Can contingency management help people with psychosis give up cannabis? The CIRCLE trial

ben-sweet-2LowviVHZ-E-unsplash

Ian Hamilton summarises the recently published CIRCLE trial, which looks at the clinical and cost-effectiveness of contingency management for cannabis use in early psychosis.

[read the full story...]

We know how to reduce premature deaths from co-morbid mental health and substance use problems, so why aren’t we doing anything about it?

shutterstock_1397419571

Ian Hamilton looks at a Swedish 42-year follow-up study, which looks at the impact that psychiatric comorbidity can have on premature death in a cohort of patients with substance use disorders.

[read the full story...]

Adolescent cannabis use and risk of depression and suicide

shutterstock_618029801

Benjamin Janaway blogs about a major data analysis that links adolescent cannabis use with increased risk of depression and suicide. He considers the opportunities for early recognition of cannabis use and public intervention.

[read the full story...]

Daily skunk cannabis use associated with a 5-fold increase in psychosis risk

lexscope-388938-unsplash

Luke Sheridan-Reins explores a recent paper on the contribution of cannabis use to variation in the incidence of psychotic disorder across Europe.

[read the full story...]

Cannabis use in the developing brain: evidence from a recent cross-sectional meta-analysis

25102549652_db548ac089_k

Joe Barnby considers the findings of a recent meta-analysis of cross-sectional observational data, which explores the association of cannabis with cognitive functioning in adolescents and young adults.

[read the full story...]

What can genetics tell us about the link between cannabis and schizophrenia? #MHQT

chase-fade-1055517-unsplash

Suzi Gage summarises a recent GWAS of lifetime cannabis use, which reveals new risk loci, genetic overlap with psychiatric traits, and a causal influence of schizophrenia. Interesting new evidence ahead of our Mental Health Question Time #MHQT event in London tomorrow.

[read the full story...]

Medical cannabis for mental illness: current use is not supported by research #MHQT

sharon-mccutcheon-798864-unsplash

As we prepare for our Cannabis #MHQT event on Wed 26 Sep, Luke Sheridan Rains dissects a narrative review that asks: Is cannabis treatment for anxiety, mood, and related disorders ready for prime time?

His answer is that current evidence does not support the use of medical cannabis for mental illnesses such as anxiety or depression.

[read the full story...]

Is Cannabidiol (CBD) an effective antipsychotic?

24281909498_a080b71a94_k

Luke Sheridan Rains publishes his debut blog on a recent multicentre RCT of Cannabidiol (CBD) as an adjunctive therapy for people with schizophrenia, which suggests that CBD had a beneficial, but modest impact on positive psychotic symptoms and severity of illness when used alongside existing antipsychotics.

[read the full story...]

Joint risks? Tobacco and cannabis and psychotic symptoms

joints

James MacCabe appraises a recent study, which looks at the association of combined patterns of tobacco and cannabis use in adolescents who go on to experience psychotic symptoms.

[read the full story...]